Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.

Academic Article

Abstract

  • Adjuvant Interferon (IFN) was given to increase tumor antigen expression and enhance localization with 131I-labeled CC49 radioimmunotherapy in a Phase II trial for hormone resistant metastatic prostate cancer. Patients received four doses of alpha-IFN (3 x 10(6) IU) s.c. on alternate days, from day -5 to day +1 of 75 mCi/m2 131I-CC49 treatment. Toxicity was well tolerated, with the majority of patients experiencing transient grade 3 or 4 neutropenia and/or thrombocytopenia (maximal at 4-6 weeks). The absorbed dose was >25 Gy in four of eight tumors visualized, which represents an increase of >20 fold over whole body radiation dose. Two patients had radiographic minor responses by 6 weeks post-therapy, whereas five of six patients experiencing pain had symptom relief without radiographic changes. The protocol provided modest antitumor effects (pain relief in five of six patients and two minor radiographic responses). This study suggests that the addition of IFN enhanced tumor uptake and antitumor effects as compared to a prior Phase II trial of 131I-CC49 alone.
  • Published In

    Keywords

  • Aged, Animals, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Antigens, Neoplasm, Glycoproteins, Humans, Interferon-alpha, Iodine Radioisotopes, Male, Mice, Middle Aged, Neoplasm Metastasis, Prostatic Neoplasms, Radioimmunotherapy
  • Author List

  • Meredith RF; Khazaeli MB; Macey DJ; Grizzle WE; Mayo M; Schlom J; Russell CD; LoBuglio AF
  • Start Page

  • 3254s
  • End Page

  • 3258s
  • Volume

  • 5
  • Issue

  • 10 Suppl